Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 17Breast Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 4Fallopian Tube Neoplasms 4Sarcoma 3Solid Tumor 2Small Cell Lung Carcinoma 2Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Cancer Metastatic 2Advanced Solid Tumors 2Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Stomach Neoplasms 1Sarcoma, Ewing 1SCLC, Extensive Stage 1Platinum-sensitive Relapsed Ovarian Cancer 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Kenny-Caffey syndrome, Type 1 1Her-2 Negative Breast Cancer 1Glioblastoma 1Fludzoparib" and Anti-angiogenic 1Female Breast Cancer Patients 1

Interventions

Cisplatin 123Gemcitabine 70Radiotherapy, Intensity-Modulated 56toripalimab 39Capecitabine 36Fluorouracil 33Docetaxel 32Radiotherapy 24camrelizumab 23Drug Therapy 20nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12apatinib 11Chemoradiotherapy 11tislelizumab 10sintilimab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Induction Chemotherapy 10Immune Checkpoint Inhibitors 10Specimen Handling 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nasopharyngeal Carcinoma × fluzoparib × Clear all
NCT04978012 2022-06-07

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Fudan University

Phase 2 Unknown
48 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡